Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totaling 441,245 shares, a growth of 279.6% from the April 30th total of 116,241 shares. Approximately 8.6% of the shares of the company are sold short. Based on an average daily volume of 3,204,496 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Shuttle Pharmaceuticals

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $37,000. Ikarian Capital LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $124,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the third quarter valued at approximately $357,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, May 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Shuttle Pharmaceuticals has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Down 5.6%

Shares of SHPH traded down $0.03 during trading hours on Friday, reaching $0.51. The company had a trading volume of 112,491 shares, compared to its average volume of 2,101,171. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $1.31. Shuttle Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $6.19. The company has a market capitalization of $2.97 million, a price-to-earnings ratio of -0.11 and a beta of 0.38.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its earnings results on Friday, May 15th. The company reported ($0.43) earnings per share for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .